Stocks Drop After Strong Jobs Report… And Next Move In The Weight Loss Drug Space 1/10/25

10 Jan 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" - Episode: Stocks Drop After Strong Jobs Report… And Next Move In The Weight Loss Drug Space (1/10/25)

Episode Overview In this episode of CNBC's "Fast Money," hosted by Melissa Lee with traders Tim Seymour, Courtney Garcia, Steve Grasso, and Julie Beal, the discussion revolves around a significant drop in stock prices following a stronger-than-expected jobs report. The episode also highlights the upcoming JPMorgan Health Care conference, focusing on the weight loss drug market and the industry's competitors.

---

Key Topics Discussed

  1. Market Reactions to Economic Data
  2. Stocks Sell-Off: All three major indices fell over 1.5% after the jobs report revealed:
  3. Payrolls increased by over 250,000 in December.
  4. Unemployment rate decreased to 4.1%.
  5. Investor Concerns: The market is reacting to Federal Reserve policies, with volatility reaching three-week highs.
  6. Interest Rates:
  7. 10-year treasury yields approached 4.8%, while the dollar strengthened to its highest level in over two years.
  8. The discussion on whether the market is prepared for more volatility based on upcoming inflation reports.
  1. Federal Reserve Insights
  2. Market Sentiment: Traders express that despite volatility, it doesn't necessarily imply a bearish outlook.
  3. Fed's Stance: The Fed's approach remains data-dependent, making it unclear if rate cuts will happen any time soon.
  4. Inflation Outlook: Economists worry about inflation pressures influencing Fed actions.
  1. Year of the Obesity Pill
  2. Focus on Obesity Drugs: The upcoming JPMorgan Health Care conference is expected to spotlight obesity medications.
  3. Market Opportunities:
  4. Pharma companies are gearing up for significant announcements related to next-generation weight loss drugs.
  5. Expectations for major clinical trial results from companies like Lilly and Pfizer.
  1. Sector Highlights
  2. Delta Airlines: Shares surged after strong earnings and optimistic guidance for 2025, indicating robust demand in the airline industry.
  3. Constellation Energy: Following a significant acquisition, the company’s stock reached new highs, showcasing strength in the energy sector.
  4. Luxury Market: Capri Holdings saw stock movement due to reports of potential acquisitions and upgrades from analysts.
  1. Broader Economic and Market Implications
  2. Interest Rates & Valuations:
  3. Discussion on how rising rates may impact stock valuations, with potential shifts in market dynamics.
  4. Concerns about how to balance growth expectations with rising interest rates, emphasizing the need for investors to remain fundamentally focused.
  5. Impact of Global Factors: Global economic indicators and central bank policies influencing U.S. markets.

---

Key Takeaways

  • A strong jobs report can lead to market volatility and shifts in investor sentiment regarding the Fed's interest rate policies.
  • The weight loss drug market is poised for significant developments, reflecting broader healthcare trends.
  • Investors are encouraged to focus on fundamentals amid rising uncertainties and changing economic landscapes.
  • The airline and energy sectors are highlighted as examples of resilience and potential growth opportunities.

---

Conclusion This episode of "Fast Money" encapsulates a complex interplay of economic indicators, market reactions, and sector-specific developments, particularly focusing on the implications of the jobs report and the anticipated changes in the healthcare landscape. Investors are advised to remain vigilant and adaptable in the face of evolving market conditions.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live from the Nasdaq market site in the heart of New York City's Times Square this is fast Here's what's on tap tonight. A post-job sell-off. Stocks sinking, yields spiking, and volatility hitting three-week highs as concerns grow about where the Fed is heading. We break down all the moves and how next week's CPI print could factor in. And the year of the obesity pill. Pharma companies seem to have a singular focus this year where the top players stand in the race and the stocks that could see the biggest gains. Plus, Delta shares take off as earnings season gets underway. Constellation Energy hits new highs on a blockbuster power deal.

0:33and its deal with tapestry may be done, but Capri may have another idea in mind. The luxury details coming up. I'm Melissa Lecombe, live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Courtney Garcia, Steve Grasso, and Julie Beal. We start off with a major sell-off on Wall Street. All three indices tumbling more than 1.5 % after this morning's stronger-than-expected jobs report. Payrolls growing by more than 250 ,000 in December, while the unemployment rate fell to 4.1%. Today's market dropped, nearly erasing the entire post-election rally. Just one week to go until President-elect Donald Trump's inauguration.

1:08The Dow is now below where it was on Election Day. The S &P 500 basically flat since then. The Nasdaq still holding on to a less than 4 % gain. And while equity sold off, the dollar and treasuries, they ticked higher. Ten-year closing in on 4.8%, its highest level yield-wise since November of 2023. The 30-year hitting 5 % at one point. the dollar at its highest level in more than two years. All this action ahead of two key inflation reports coming next week, both producer and consumer prices expected to accelerate from November level. So do all these moves set the stage for even more volatility to come?

1:44Tim? They do, but volatility doesn't necessarily have to be bad and doesn't necessarily have to derail what's been one of the greatest two-year bull markets of all time. You know, my view is that this week was all about central banks. It was all about yields blowing out around the world. I mean, look what happened in the gilt market. I know most people don't. So I'll just say, if you look at Japanese yields, they've moved even faster than U.S. yields, and they are breaking to significantly higher levels, at least relative to themselves. What we learned this week in Fed Minutes was that the Fed, in their last meeting, was very much on hold.

2:16What we heard from the St. Louis Fed is that effectively since September, his view is the world has changed. This is a new voting member of the FOMC, and that it's very clear within the Fed that is so data dependent that, look, if anything, we're now out to March at best on a cut. And yes, that's what the market is digesting. It's been like it's been a lose-lose market for equities and bonds over the last five weeks. We haven't done this since back to 2023. But it feels a lot like it feels a lot like, you know, the early stages of when the Fed was telegraphing that they were hiking. We're not getting anything close to that.

2:51Of course, that was historic in terms of what they did in the end of 21 into 22 and 23. But, you know, markets came into all of this with cash levels for professionals at lowest levels we've seen in a long time. Complacency, Bitcoin going through the moon. I mean, we came into this period of rising rates set up for volatility. Volatility, not comfortable, not always bad. So an excuse to lighten up positions or is the pace of this rise in rates, is that actually scary? Does that actually factor into a revised outlook for stocks for you? Well, I think the bigger problem would be interest rates rising, which you bring up.

3:28And I think we're far away from that, so I don't think that's anything to consider. But you're starting to see more inklings and kind of the rumors of people starting to talk about that. So when you're looking at no rate cuts happening this year, that went from a 13 % odds to 25 % odds when we look at today. So I don't think rates staying this higher for longer is necessarily a bad thing for the markets. They need to digest that, which is what's happening today. But if they stay there, I think markets can likely continue. But we just don't want to see them going higher. I don't think we're there yet, so I wouldn't really price that in.

3:54I think we pulled a lot forward, but the way you opened up the show with that litany of data points, the fact that we're so close to all-time highs, isn't that something to take away? I think Tim touched on a lot of the good news in the marketplace. So if you went through that litany, the game that you always play, if you would have known the entry, where would the market be? And you could make the case that the market could be substantially lower than it is. the odds of Donald Trump becoming president again were probably pretty low. And as we got closer, it was still a flip of the coin. When he was elected, huge pro-growth, huge CapEx.

4:37So there were a lot of things that were really in the bull's corner. So I think the market is just adjusting, if you will. OK, there could also be a little bit of Julie Beal. Well, you know, upon the election, there are all sorts of assumptions about all these pro-growth sort of policies. And as we get closer to Inauguration Day, there is this reality setting in that, you know what, day one, there could be tariffs. We don't know the extent of the tariffs. There are all these potentially inflationary policies coming down the pike. And we're at, you know, 4.74 and change. Yeah, I think that's exactly it.

5:09I think there was a recognition in the markets that we could have a higher level of inflation. But I think what people weren't necessarily expecting was that, you know, other pockets of the economy would be as strong as they are. And I think this labor report really points to an underlying very healthy economy. And so I think taken together, it's getting very, very difficult for the Fed to be in any kind of position to be able to cut rates. For sure, I think they're going to have to stand still. I think the discussions that people that are starting to have about raising rates, I mean, I can't even imagine that discussion, you know, four weeks ago.

5:43and suddenly I'm hearing it more and more. I think that's just a level of indication of how wide the cone of outcomes has become. And that happens anytime you start to really ramp up the level of uncertainty. And I think with this administration, that's just a reflection of the fact that the cone of outcomes is wider. We're going to have more volatility because we can't really predict outcomes. And I think it's really the time for investors to focus more on the fundamentals because come earnings, that's when things are going to get trued up in the right way. Bank of America previously expected two rate cuts this year, now expects none.

6:17The economists there are saying the conversation should move to hikes if inflation drifts higher. So it's in print from a major bank, from a major economist. And it's not all that provocative anymore, as we've all just talked about. But I think if you go back to the number today and the unemployment rate of 4.1, and you look at where at least major focus in policy is around immigration. and that's all types of immigration and whether that was legal, whether it was illegal. And there's a lot of strong opinions on it. But there's no denying that the immigration into the country over the last three years was three times what it had been in the previous, on average, per year over the previous 15 years.

6:56And that was significantly important to a labor market and significantly important to an economy that actually relished that. I mean, again, I will stay away from the immigration issues that are very topical everywhere else. But as it related to the job market and where it made the Fed's job easier or where, in fact, at least it took some of the pressure off of a labor market that is largely normalized. I just bring that up because today was really as much about the unemployment rate, which we often say is more symbolic. It can move around. But I think the inflation dynamics that are at least out there today are certainly to be reckoned with.

7:29I think a stronger dollar is certainly a nice offset. And we'll hear that, though. But I mean, hey, we've got earnings season coming up. It's not that, you know, we started as we head into next week, we start to look straight into the barrel of earnings season. The banks are going to tell you first they're going to talk about a steeper yield curve. But a lot of these multinational industrials and 28 percent of the S &P revenues, people know these numbers are coming internationally. So some of that is good. Some of that is bad. Companies don't. I mean, if you're a company and you're going to report earnings, there are many companies out there about to do exactly that.

8:01Would you go out on a limb and be bullish given the volatility to come? Is it in their interest to be bullish about their forecast, even for the next, you know, six months? What do you think? It depends. I think, judging on the election outcome, I think that you have a lot more horizon to see or distance that you could see that tax policy, taxes aren't going up. CapEx is probably going up. So there's a lot of things that you can invest around with a clearer tax policy. you can become bullish, but a CEO is never rewarded for being overly bullish. They're always rewarded for kitchen sinking and for lowering the bar and expectations.

8:44So and analysts, by the way, are rewarded for the same type of thing. But I think Tim talked about the dollar. You know, you talked about a lot of these things. They seem very overextended to me, as we talk about on a regular basis. So I think inflation, CPI, 30 percent of CPI is housing. Could there be another outlier print? Yes. I think everything is overextended. Well, I think CEOs are going to comment industry specific. And let's face it. I mean, there are industries that are going to benefit from a higher rate environment, a stronger labor market, et cetera, et cetera. I think it's going to get back to fundamentals.

9:20I think we have to look for the markets at 10 and a half percent EPS growth in 2025 at 22 times forward and say, is this the market? Is this where we should be? And that's really the question. The question is also going to come right back to those seven stocks who have priced a lot of great news in, but whose businesses, if you look at the internet space, and I was listening to Mark Mahaney today on a webinar with Evercore, I mean, he says they come into 25 in much better shape than they did into 24. So, you know, in terms of the true demand of what's going on, the ad business, the ad component of it, but obviously everything from data center and certainly the consumer strength that's driving a lot of this.

9:56So it's going to get back to these big stocks again. And I think these big stocks are going to be somewhat defensive in a higher rate environment. A stronger economy. A winner in any environment. Still the MAG 7. The magnificent 7. Still magnificent. I see what you did. No, you did it to yourself. I'm just repeating your words back at you. Are they defensive? I mean, they can be. But I think what we've talked about is they are still getting expensive. And so I still think we want to own those. I don't want to get out of them. I just still think there's a lot of other areas that you can add your money to right now.

10:28And I think when we're looking at what's going on right now with the jobs numbers, it's showing we have a strong economy. And I think this is where likely equity markets can get past this if we have these higher for longer, but the economy is still strong and consumers keep spending. I think the issue is, does inflation get to a point that the consumer is weakened? And I think that's something that I always like to hear when the banks report earnings, because they have a really good grasp on is the consumer still spending. I think that's what you want to listen to next week. All right. For more on the markets and the economy, let's bring in CNBC contributor Peter Buchvar.

10:56He's a Bleakley Financial Group chief investment officer. Peter, always great to have you. You think 10-year yields are going to hit 5 percent? What happens to stocks in that scenario? Well, just to add some what Tim was saying is it helps to self-actualize. Do you want to be paying 22 times forward earnings in that rising rate environment? When rates are low, investors can be very valuation agnostic. When investors believe that the Fed is going to cut short-term interest rates and save us, investors can be valuation agnostic. But when you hit the reality that interest rates have actually risen across the curve in the face of those rate cuts, and now the Fed may not even cut again, well, valuations may all of a sudden matter.

11:38And instead of 22 or 23 times, maybe 20 times is more appropriate, maybe 17 or 18. Well, if that's the case, then it's going to be tough for the market to drive much higher. Now, the market can say, OK, we're comfortable 22, and we can sort of not have much of a return this year if we've already priced in a lot of the gains. But this P multiple now all of a sudden becomes an attention focus if these rise in rates continues, which I think it will. And yes, 5 percent, I do think, will be touched again that we saw last summer. So markets go down in your view, Peter. I mean, that's the bottom line.

12:13And is the bar for a Fed rate hike much lower in your view? Or is that still off the table? I don't think that's not where the Fed's head is. And I look at the payroll number today, and it just doesn't square with anything else I'm seeing. To me, job growth is probably more around the$150 level, because while we celebrated the$256, which does include about 30 ,000-plus of government, you know, ADP on Wednesday said private sector was just$122. I think the truth lies somewhere in the middle, and it's probably about$150. And that's a slowing rate of job growth relative to 2023. So I don't think the Fed's head is there.

12:55Now, of course, the inflation data next week is going to be big. If there's one thing that can sort of take the heat off interest rates, it could be a benign CPI number, which I think the services component can deliver that. But there's also more that's going on here. It's the global rise in interest rates. I mean, you essentially have the global bond police that's driving through all the different neighborhoods around the world and calling up governments that have excessive debts and deficits and wondering whether they're going to be able to sell that at the price these borrowers want to sell at.

13:27Whether it's Japan, whether it's the U.K., France. And it's now becoming wider spread. It's falling into Germany, which is economies in a recession and with higher interest rates. And Australia and Canada. And also one last thing with rates that's not really being discussed around markets is the Bank of Japan is probably going to raise rates this year. I'm sorry, this month. And they continue to reduce the pace of their QE. Through the first quarter of 2026, they will have cut QE in half. That is a major liquidity spigot that's being turned off that I think is behind the scenes impacting global interest rates, just as it did last summer when they eliminated yield curve control and the U.S.

14:0810-year yield within days started its ascent to 5%. Peter, when you look at the revisions that we've seen last year in the jobs numbers, we saw the biggest revision since 2009. Do you think that could be a little wonky in the differential that you talked about? And secondly, when you take out MAG-7, you're concerned with valuation. When you take out MAG7 and you look at forward versus forward without MAG7, it's a couple of percentage points different. When you look at current, it's about 10 handles different. Agreed. You can drive a truck between the P multiples of the growth stocks and the multiples of the value stocks.

14:51I think this is the ideal situation where value finally catches up to the growth trade and that the stocks most vulnerable are those growthy high PE multiples. Those that are less vulnerable are the cheap value stuff. Now, with respect to the revisions, when you think about here we are just a week after December ended and the government is supposed to come up with an accurate jobs number, it's just physically impossible. And that's why we get a revision next month, a revision the following month, a revision a year from now. And that final number is going to be very different than what we heard today.

15:21And it's also just because there are less businesses that are responding to these surveys and so on and so on. So that's why I think when you analyze the jobs data, you've got to look at it all together with a lot of different data points. Peter, always great to speak with you. Thank you. Thanks. Have a good weekend. Peter Bookfar of Weekly. So it sounds like Peter says there are a lot of global factors that will sort of fuel the rate rise further. Julie Beal, in your world, your corner of the market has been absolutely crushed because of rising yields. And so, you know, for you who focus on quality names, those names get crushed too?

15:58I mean, we've demonstrated that they tend not to, right? A lot of the names that we own, we really try to focus on names that have cash positions rather than any kind of leverage. And so weirdly, a lot of the companies that I own have actually benefited from higher interest rates. And That's not really a fundamental issue here or there. But the most important thing is that these companies have, they are really the masters of their own destiny. And I think that's actually what's critical when you have this level of uncertainty is that you have companies that have the financial flexibility to be able to respond to changes in markets.

16:30And that's something that typically small cap companies struggle to do. And so I think if you can be really selective and choose those kinds of higher quality businesses that have a lot of earnings persistence, you end up doing well through a cycle like this. All right, let's get to what's happening out west. Southern California continuing to battle massive wildfires. The blazes killing at least 10 and forcing the evacuation of over 180 ,000 residents. Thousands of streets completely destroyed. AccuWeather estimates on economic losses and damages have tripled to$150 billion, with insured losses pegged at$20 billion by insurance analysts.

17:08CNBC's Contessa Burr joins us now to break down the current impact on insurance. And we were chatting in the green room. This is really a crisis in this industry. It is at an inflection point where several CEO insurance executives have said to me today, look, this has the real potential of becoming an insurance desert. And it depends on how the insurance commissioner in California, how the state legislature responds to this crisis, whether they can come out of that. But$20 billion in insured losses would make this the costliest wildfire event for insurers in global history, anywhere. And really, this is a homeowners event.

17:48It's far more exposed in homeowners than commercial property or, say, agriculture. The California insurance commissioner issued a moratorium on the cancellation or the non-renewal of residential properties. My sources tell me commercial insurers are already putting a halt on new policies and instituting across the board non-renewals for policies that come due while the wildfires are burning. That's how insurers reduce their exposure if they think the risks are too high for the prices they can get. And the fair plan, which is California's last resort insurer, has hundreds of millions in total billions, hundreds of billions in total exposure, with only hundreds of millions in reserves.

18:31And we know$6 billion in exposure in the Pacific Palisades alone. There is no way my sources say that they're getting$6 billion in premiums. 85 % growth in the number of policies there between 2023 and 2024. So that may not account for all the cancellations that we know State Farm handed out in that area. If the fair plan runs out of money to pay these claims, and by all accounts, it probably will, every insurer that has operated in this state for the last two years will have to pay in proportion to its market share. So that means State Farm, which has somewhere in the neighborhood of 19 percent market share in the state and which canceled about 1 ,600 policies in the Pacific Palisades last year, will now have to pay out on claims for which it never collected premiums.

19:21Not only that, what's going to happen? I got a big warning on this today, Melissa. What people thought they were insuring. Say you had a$4 million house in the Palisades and you went to your insurer and you said, OK, I'm going to get this coverage. Your insurer may now say because of the inflation of materials, wait a minute, it's going to cost$5 million or$6 million to replace that house. And you only have a policy for$4 million. So there may be a lot of people who are way underinsured. And then that sparks the kind of lawsuits that have been a consistent headwind for this industry. The litigation that happens gets passed on to every policyholder everywhere, not just in California.

20:05So you live in New York, New Jersey. You're not anywhere close to the wildfires, but you will see your premiums go higher, most likely. Because the way insurance works is that it's a risk pool. If you have a lot of people paying into the same pool, then you don't have to take all of the risk when a tornado hits in the Midwest. But yes, if it goes up, if we see California, if we see Florida, the other states that are heading toward this direction, New York, New Jersey, Illinois, if we see them follow this path, what this means is everyone in the nation is going to see their home insurance premiums go up beyond what they've already seen.

20:43I was going to say, it's already been a rough couple of years. Yes, that's right. It's hard to believe that, but that's right. And how much of this is a function also of just how loosely regulated some of these other states are? There was an article in the Journal about that today, and that's part of where it can go. I mean, the fingers have been pointed at this particular administration in California that the commissioner gets requests to hike the rates and sits on them and sits on them and sits on them. Doesn't say no, just lets it lapse. And then finally, when Allstate goes through and finally gets almost a 30 percent hike for property insurance and the homeowners are shocked by this, instead of seeing incremental.

21:21Right. Then what you say is, is that enough? No, no, that is not enough. Contessa, thank you. Contessa Brewer. Coming up, Delta takes the flight. The numbers that have CEO Ed Bastian saying 2025 could be the airline's best year ever. Plus, the clock is ticking on TikTok. The Supreme Court could soon decide on whether to ban the popular social media app. Could that be a big win for names like Meta and Snap? We'll get some answers next.

21:57Welcome back to Fast Money. Shares of Delta topping the tape today after beating earnings estimates and posting strong guidance. The company is saying it expects to generate more than$4 billion in free cash flow this year. That's 18 % more than 2024. Shares seeing their best day in more than three years. CEO Ed Bastian on Squawk Box this morning saying 2025 could be its best year ever. We're looking in the first quarter. close to double digits in terms of top-line revenue growth. We're looking at doubling our EPS in the first quarter. We're looking at next year being the top financial performance in our history.

22:33You've got corporates up double digits. You've got the international up close to double digits. You've got our AmeriExpress loyalty, remuneration and spending at double-digit levels. So every aspect that we're putting out, again, many of these in premium categories, are really, really healthy. All right. So can Delta keep going higher? We were just talking about CEO guidance and how it's not in their best interest to be really bullish, unless they're really sure that it's going to pan out, Tim. Well, what's interesting is Delta's really provided a halo effect for the entire industry. It's not that they're not also doing a better job.

23:08I mean, the whole industry is run differently. And the question for investors here, when Delta's trading probably 30 % north on multiple and a forward multiple to its five-year average, and even more so on a 10-year, And again, it tells you those averages bake in how poorly run airlines were in the past and how we expected them. Anytime there was an opportunity to actually take advantage of good news, they overbuilt out capacity. They became very inefficient. What they're doing now is totally different. And what they talked about today in those four Q numbers were that their revenue per available seat miles, otherwise known as RASM, was was up 160 basis points and that they expected to go even higher.

23:43So I think you stay in what used to be the greatest trading stocks in the world into now what are investable stocks. And I think it's been a huge run. You have to chase it today. There's a lot more Fast Monday to come. Here's what's coming up next. The clock is ticking on TikTok. It's fate hanging in the balance as the Supreme Court hears arguments over banning the social media giant, what it means for the industry and its top competitors. Next. Plus, is 2025 the year of the obesity pill? The skinny on that and the biggest topics from J.P. Morgan's healthcare conference. From Alzheimer's to AI and beyond.

Read the full transcript

24:22You're watching Fast Money live from the NASDAQ market side in Times Square. We're back right after this.

24:35Welcome back to Fast Money. TikTok's days could be numbered. The Supreme Court hearing oral arguments today on whether to ban the social media giant over its ties with China. CBC's Eamon Javers has got the latest. Eamon. Hey there, Melissa. No decision on the fate of TikTok today from the Supreme Court. Just nine days before a legally mandated deadline for the Chinese company ByteDance to divest itself of the popular social media application. The justices heard arguments today from attorneys for TikTok, a group of TikTok creators and the Biden administration, which is seeking to uphold the law, which passed with a big bipartisan vote.

25:11Now, TikTok argued today that the Supreme Court should delay implementation of the law, which takes effect just one day before President-elect Trump takes the oath of office on January 20th. Trump, who once supported a TikTok ban himself, now opposes it and has asked the court to delay the deadline so he can work out a political deal once he's sworn in on that date. The arguments today centered on who is protected by the Constitution's guarantee of freedom of speech, whether that's ByteDance, which is a Chinese company and doesn't have freedom of speech rights. But maybe TikTok US, the American subsidiary, does have those rights.

25:50And TikTok argued that American content creators have a right to express themselves, and that would be impacted by a TikTok shutdown. TikTok's attorneys said the app could be forced to go dark on January 19th if the law is upheld, but a Trump administration coming in the next day could usher in an entirely new world. Now, the court did not give a deadline for making its final ruling here, but a decision could certainly come next week. Melissa, back over to you. All right, Eamon, thank you. Eamon Javers. And of course, in the past, we said this could benefit the likes of a Meta, a Snap, etc. A court, what do you think?

26:26Is there a trade still there? Yeah, I would say if you're looking to trade this, I would actually argue that a snap is probably a better beneficiary than a meta. I think you're kind of seeing that the reels from meta is going to benefit from that. But I think getting the younger cohort who's on TikTok, you already see that even today like that had a bigger bump. I wouldn't trade it based on just that. However, I mean, I think this is a political football that's thrown around. You're seeing how they're talking about this. Trump is already coming in and saying, I oppose this. This happens the day after or the day before he comes in office.

26:54So, yes, could it benefit snap? Probably. I just don't know if it's that realistic. I'd probably stay out of it for that reason. I think you're going to see Meta with that move towards Trump. That will be the eclipse. That will be the real tailwind for that stock. So still bullish on Meta with or without this ban on TikTok. I agree with Court. Snap has the most direct because of the age group of people that are using Snap. And I also agree that if Trump is already talking about he wants to have a political decision on it, he's erred on the side of letting it exist. So whatever run-up we see in SNAP could really be wiped out immediately.

27:30Back to SNAP, I also just think in terms of who has the chance to benefit more from a little bit of upside. I mean, the news around SNAP, for the most part, has been horrific for a year and a half. Now, off those Q2 numbers, which really sank it, it's a pretty decent six-month chart. I'm actually long some SNAP here, so I like this move. Coming up, a deep dive into the biggest topics of the J.P. Morgan Healthcare Conference. Will GLP-1 heavyweights finally tip the scales on obesity pills? The skinny on that and much, much more. Overload.

28:01Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

28:18Welcome back to Fast Money Stocks. Dropping sharply to end the week as investors react to a strong jobs report and the impact it may have on the Fed's next rate decision. The Dow and S &P 500 having their worst day since mid-December, and the Nasdaq closing out its worst week since November. Meanwhile, Hershey announcing CEO Michelle Buck plans to retire in June of next year. She'll continue to serve in her roles until a successor is named. Buck has been CEO since 2017. J.P. Morgan's annual health care conference kicks off on Monday in San Francisco, bringing together the industry's biggest names and emerging players.

28:50Obesity, of course, set to play a prominent role yet again, with investor focus now turning to the next generation category of weight loss drugs and the role of pills in the booming market. Our Angelica Peebles joins us now with the details. Angelica, of course, it's obesity that's going to hog the attention. Of course, but this year it's all about the obesity pill. Now, the biggest event on the calendar is the readout of Lilly's Phase 3 trials of Orforglopron. Now, we're expecting to get the first look in April with more data throughout the year. And before that, we should get an update from Pfizer on its plans for its experimental pill, Denuglipron, which is currently in dose optimization studies.

29:26Then in the second half of the year, we should get phase two data from both Viking and Structures pill candidates. And the question for everyone is really, where does a pill fit into the treatment of obesity? Goldman estimates that pills will make up about 30 percent of the market in 2030. And we also want to hear about what's important for an obesity pill. Nobody expects them to deliver more weight loss than the injectables, but side effects could be even more important for a pill. Goldman's Chris Chibutani explaining that for pills to live up to this idea of democratizing use of GLP-1s, they'll need to be prescribed by primary care doctors, and those doctors might not want to manage those side effects as closely as some of the specialists.

30:03On Monday, we'll be live from the conference talking to Pfizer CEO Albert Bourla and Structure CEO Ray Stevens, asking for the latest updates on the key trials to watch and much more, Melissa. All right, Angelica, thank you. Angelica Peebles, for more on what investors can expect at JPM, let's bring in Portal Innovation CEO John Flavin. The VC invests in early-stage life sciences companies, also providing lab space and industry partnerships to its portfolio companies. John, great to have you with us. Hi, Melissa. Great to see you again. You will be there, of course. How will the tone be different because of an incoming Trump administration in terms of dealmaking, et cetera?

30:39Yeah, I mean, 2024 was a relatively rough year for biotech, biopharma, and pharma stocks. The dampers last year were primarily inflation, and then you had the election uncertainties. With the election behind us, there was an initial concern around who is coming in as head of HHS. That noise is starting to subside, but the stocks really took a hit toward the end of the year. As you enter into 2025, I think there's reason for optimism. With inflation generally in check, with tax cuts on the horizon, which favor riskier bets and riskier stocks, as well as an administration that I think, outside of the noise and hype, will be quite friendly to biopharma and pharma as it relates to pricing, and also the FTC.

31:32JPMorgan is such an exciting event. I think it will be an event that would be looking toward a more optimistic, hopeful 2025. And I think that you're going to see a lot of venture activity leading in that respect. The public biotech markets, I think you're going to see more IPOs come back and a lot of deal making beginning to happen with a friendlier FTC and markets that are not as afraid of inflation overhang. You're going to see a lot more activity in the biotech sector. In terms of VC money, John, maybe a year or maybe two years ago, So it was, you know, anything that had to do with obesity would get money.

32:10How has that changed if at all, I mean, given the performance of the publicly traded stocks, you know, weren't as strong in 2024? Yeah, I think you're going to continue to see investments go into the obesity space, but that won't be the only space where you're going to see the investments taking place. You know, certainly I think a key theme will be large market opportunities. So writ large, that's cardiometabolics within which you have the obesity opportunities. I think that the obesity opportunities that people are going to be looking at going forward will be to work and identify, you know, pill form, looking at side effects with the GLP-1 agonists, especially long term, looking at drugs that might be able to preserve or build up muscle mass are going to be the next generation where you'll see a lot more investment activity.

33:00But I think you will also see continued investment in neuro. There's going to be a lot more activity where you're starting to see the blending of devices like Neuralink and bioelectronics that will impact disease of the brain, but also some important drugs that I think will come forward to treat Parkinson's. We saw the big deal with Corona and BMS last year in the approval of their schizophrenia drug. I think that's going to garner a lot of investment into that space as you look forward into the future. In terms of the next generation of obesity, John, you'd mentioned all the things that are already in development that investors are expecting to have sort of, you know, readouts in the next year or so, whether it be oral medications or medications that also preserve muscle mass.

33:47Those are firmly in investor expectations, I think, in terms of what is coming to market. What are the things that you're investing in that are years down the line that we're not even thinking about that will leapfrog that next batch of obesity development? Yeah, well, Portal is very focused on early stage investing. So oftentimes, you know, we're investing first institutional money going into companies like Pelagos Pharmaceuticals. They're developing an exercise mimetic. We're particularly excited about this potential mechanism. Again, albeit very early in development. An exercise mimetic activates certain pathways that are beneficial for various diseases.

34:28And so if we can mimic what it's like to exercise, then we may have better effect on weight loss and preserving or building up muscle mass long term without the side effects. But also other related diseases that would benefit from exercise that we think about, you know, diabetes, Alzheimer's. So we're really excited about Pelagos. And then, you know, a company that spun out of MIT, Bob Langer's lab and Geo Traverso's lab, still early in development, but approaching human clinical trials, a company called Sintis, which just unveiled some recent data showing very promising results that would be an alternative mechanism to the drugs that are currently being developed in the marketplace that you hear about today.

35:12Right. Bob Langer being, of course, a founder of Moderna. John, fascinating discussion. Thanks so much for joining us. Great to see you, Melissa. John Flavin of Portal. Julie Beal, how do you think about the environment for biotechs next year? John had mentioned IPOs coming to market and just an overall better year for them. Yeah, I think the overall outlook looks it's increasingly getting more sound. It's starting to become more investable. You're seeing higher quality coming to the market. And I think part of that is just a function of we had so many, we really kind of overdid it. And now the kind of quality as we've been through this difficult period has really yielded much higher quality businesses.

35:53And so I think if you are a biotech investor, which we aren't, but I think if you are, I think you're going to start seeing more compelling opportunities for sure. Coming up, a crude comeback. Texas Tea hitting its highest level since October. The energy names are the biggest opportunities to capitalize on the rise next. Plus, another big shakeup in the luxury space, how Capri is wheeling and dealing with one of the biggest names in fashion. That's next.

36:26Welcome back to Fast Money. WTI crude heating up to$76 a barrel, hitting its highest level since October 8th. This comes as new sanctions on Russia's oil industry raise risk of supply shortages. Energy prices posting their biggest weekly gain since early October as well. Tim, what do you think? I think it's more impressive when you consider the move in the dollar, too. I mean, what's going on here? These sanctions against Russia, Surrogate Neftegas and Gazprom Neft, two companies I used to follow very closely back in the day, are very close to the Russian government. And, yes, there is this shadow fleet of tankers and fleet that are out there.

37:01But I don't think this is really what's driving oil prices higher. I think people are ultimately looking at, first of all, the global economy. Some of the demand dynamics, I think, are very much in place. And I think OPEC has done a pretty decent job of holding supply down. We've seen China demand actually fall off a cliff, so around China. But in the United States, WTI, that's what it's levered to. We've seen seven weeks of drawdown, seven consecutive weeks of drawdown. So you could see this bullish push into it. And then think about it. We've had on this air, we've reported on the polar vortex.

37:33So you have some seasonality, you have colder weather, you have a lot of disruptions around the globe. But once again, if you have any profits, I would probably take them or keep them on a short leash because you're going to have President Trump coming in who's going to drill baby drill. All right. Meantime, a big deal in nuclear, the largest U.S. power plant operator, Constellation Energy, saying it will acquire natural gas and geothermal company Calpine for more than$16 billion in cash and stock. The deal is one of the largest in the power sector. Constellation, which nearly doubled last year, hit another all-time high today.

38:05It's already at more than 36 percent in the first few trading days of the year. And, of course, that says a lot about this deal and what it could mean for this combined company. Yeah, and I think that's been the question with companies like these. They've done so well over the last year. Is all that optimism already priced in? And clearly it's not. And I think when you just look at how much energy we need for the grid, for artificial intelligence, for electric vehicles, there's just not enough to go around. And that's where something like your nuclear energy is going to be one of those big sources.

38:30And now with this deal, they're going to be your largest clean energy provider between that and natural gas. So absolutely, that's going to be a beneficiary for them. I don't think that supply demand story is ending any time in the near term. So, yeah, I think this is something you want to be a part of. Constellation alone has the biggest nuclear energy fleet out there. Calvine has the biggest net gas. So what Courtney was saying, what you were saying was it's the largest clean energy provider. And that is actually what that's what the data centers want. Julie, that's what, you know, AWS and Microsoft and Oracle, they all want this.

39:03Well, they want to have their cake and eat it too, right? So they want to be able to say that it's clean energy. But the thing is, is that they need baseload power that's always there, always on. And that's not really the traditional renewables that we think of in terms of solar and wind. Nuclear is a much better option for them in terms of baseload. And I think a lot of people are trying to kind of couch natural gas as being clean. And I don't think I would necessarily call it clean, but I would call it cleaner for sure than coal. And I think that that's a real opportunity for them. And the thing that's important for them, for all of these utility players, is that the demand is what's going to enable them to be able to expand their capacity and charge higher rates with their regulators.

39:41Because remember, this is still a very highly regulated area. And so that's really kind of critical to the growth story around this. Only four public IPPs to play power growth, essentially. And so there's a scarcity value there. Also, this deal is all about Texas, where demand is really growing. And this is CalPine's positioning. And I think this is a lot of a reason for doing the deal. Coming up, Capri catching an upgrade from Citi. But that's not the only news driving this luxury name higher. Inside a deal that could shake up the fashion industry. Next, more Fast Money in 2.

40:21Welcome back to Fast Money. Capri back on the M &A runway. Prada is reportedly evaluating a bid for Capri's Versace business. The news helping the stock to its best day since August of 2023. Capri also getting a boost from Citi, which upgraded the name to a buy from a neutral, raised its price target to$29 a share. Shares have been under pressure since its deal with Coach Parent Tapestry was called off back in October. Steve, you in this still? No, I had bid in Capri. I sold it off that pop on Tapestry. I thought I was going to get more of a run because Tapestry, the bid was for$57. I wound up selling it in the low 50s.

40:54Then Tapestry didn't give me the love that I wanted either. I made a little bit of money there, but I thought Karen made a good point that Tapestry could be brought up on, I don't want to, I'm parsing this, on nefarious activity or comments about why the deal should have gone through or not gone through. So I thought at a 12-year high, maybe it's time to lighten up on that. And maybe by Capri, 23 % of revenues is Versace. The bulk of it is Michael Kors. But there's a lack of premium names out there. Right. Got a lot of time for Versace products. I don't have a lot of time for this stock. You don't seem like that kind of showy.

41:36There's a time and a place, Mel. Got some pajamas? No, not pajamas. Versace ties that I think you gave me some heat about, actually, over the years. Yeah, you probably did. But this is some of the parts story. one that I think has its moment. For me, it's not now. Yeah, luxury goods, Courtney. In this environment, do you like them? Yeah, I think actually there could be some optimism for luxury goods if the consumer continues to remain strong here. I do think the sum of the parts, which Tim said, is probably this story here. So the fact that Tapestry was interested in means there is some value there, and the fact that they are willing to sell means they are going to be open to it.

42:10So I think seeing some sort of activity, especially when we get into this new administration, they are more open to M &A. I think something will probably happen here. So if you want to trade on it, it might be worth it. I'm not a part of that, but I think that's my two cents. I'm wearing Versace next week, by the way. You do that. I look forward to it. Up next, final trades.

42:33Time for the final trade. Julie Beal. Sir Caras should be a beneficiary of a better biotech environment. Tim. Mel, you're pulling for the SEC of the Big Ten tonight. I know. Obviously. I'm pulling for XLE Energy. Courtney, Delta, we touched on this earlier. It's one of the big winners. I think it's something you want here in 2025. Steve Grasso. Okta. It's the O in my acronym that we haven't unveiled yet. But you just unveiled one letter. I didn't say what it was. It's one letter. Oh, the suspense. Can I get a vowel? Thanks for watching Fast. Have a great weekend. Mad Money with Jim Cramer starts right now.

43:10All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:44To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

Stocks selling off as investors digested this morning’s stronger than expected jobs report. And with nearly all of the post-election gains fading, with next week’s inflation data cause even more volatility? Plus Obesity drugs expected to be in focus at this year’s JPMorgan Health Care conference. How the industry’s biggest names are handling competition, and the next-generation of weight loss drugs.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Stocks Drop After Strong Jobs Report… And Next Move In The Weight Loss Drug Space 1/10/25CNBC's "Fast Money" · 44 min
Listen in VO